HEALTH consortium Precision Medicine Scotland Innovation Centre has appointed a new head of business development.
The body was set up to accelerate the advancement and adoption of precision medicine, an approach which tailors treatment to patients rather than the population as a whole.
The appointment of Georgina Marczak, says PMS-IC, expands their expertise as they work to improve diagnostics, earlier interventions and optimal treatment options.
Marczak joins the team from Signant Health, and with a career in the pharmaceutical and healthcare industries, brings a wealth of experience, say PMS-IC.
She said: “The potential that precision medicine offers is truly transformative – not only in how we diagnose and treat disease to achieve better outcomes for patients, but also in the potential economic savings it can help to achieve for NHS Scotland.”
PMS-IC chief executive Marian McNeil said: “Georgina will collaborate with existing partners and promote the opportunities precision medicine offers to provide personalised treatment tailored to individual needs.
“Her role will be to connect organisations with the services we have to offer, such as world-class clinical research, high quality electronic health data, patient samples, a single healthcare provider (NHS Scotland), and large cohorts of patients with chronic disease, differentiating Scotland from many other countries.”
PMS-IC was formed by the Scottish Funding Council (SFC) in 2013.
Since its inception, the Scotland-wide hub has been working with industry, academia, health charities, the NHS and government.
Its key projects cover conditions such as ovarian cancer, MS, oesophageal cancer, rheumatoid arthritis and pancreatic cancer.
PMS-IC also delivers large scale collaborative informatics programmes with its industrial partners.
